-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Although cerebrospinal fluid (CSF) and positron emission tomography (PET) biomarkers may become the ultimate diagnostic tool for the detection of Alzheimer’s disease (AD) , we still urgently need a cost-effective, non-invasive, multi-level Methods to determine who should and should not undergo these expensive and more invasive tests
.
Recently, researchers have proposed that a multi-level neurodiagnostic process can meet these needs, and there is already evidence that blood-based biomarker profiles can be used to detect AD, mild cognitive impairment (MCI), Parkinson’s disease, and Lewis An accurate first step in dementia and AD and MCI in adults with Down syndrome
.
As the diagnostic framework of AD shifts to AT (N), in addition to amyloid β (A) and tau (T), more and more work has begun to focus on the utility of neurodegenerative biomarkers (N)
.
In recent years, a more interesting neurodegenerative biomarker is neurofilament light chain (NfL), which is a cytoskeletal protein expressed in large-caliber myelinated axons and can be released as a result of axonal injury Extracellular fluid
Although NfL can be detected throughout the lifespan, many studies have shown that the increase in NfL levels is related to the diagnostic status of AD, and it has received great attention as a potential biomarker of AD
.
A recent meta-analysis found that there is a good correlation between blood and cerebrospinal fluid NfL levels (r = 0.
There is a good correlation between NfL levels in blood and cerebrospinal fluid.
Changes in plasma NfL are also related to changes in overall cognition, attention and amyloid PET levels
NfLl level of medical co-morbidity index by race
NfLl level of medical co-morbidity index by race NfLl level of medical co-morbidity index by raceIn the unadjusted model, NfL was significantly associated with age (P <.
001), hypertension (P <.
001), dyslipidemia (P = .
02), and diabetes (P <.
001)
.
In the subset with data, considering age and gender, NfL is related to neurodegeneration (P <.
NfL is significantly related to age (P <.
Original source:
Original source:Sid O'Bryant et al.
Sid O'Bryant et al.
Leave a message here